SCHEMBL13618237

SCHEMBL13618237

CCOC[C@H]1CC[C@@H](N2CCC(N3C(=O)COC4CCCCC43)CC2)CC1

nearest known ligand 0.43

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 11/20 0.43
OPRM1 P35372 10/20 0.43
OPRK1 P41145 3/20 0.35
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1134342 1.00 OPRL1 (0.43) OPRL1OPRM1OPRK1MAPK1
SCHEMBL1134340 1.00 OPRL1 (0.43) OPRL1OPRM1OPRK1MAPK1
SCHEMBL1134343 1.00 OPRL1 (0.43) OPRL1OPRM1OPRK1MAPK1
SCHEMBL1134406 1.00 OPRL1 (0.43) OPRL1OPRM1OPRK1MAPK1
SCHEMBL1134316 0.93 OPRM1 (0.42) OPRL1OPRM1OPRK1
SCHEMBL1134391 0.93 OPRM1 (0.42) OPRL1OPRM1OPRK1
SCHEMBL1134488 0.93 OPRM1 (0.42) OPRL1OPRM1OPRK1
SCHEMBL1134348 0.93 OPRM1 (0.42) OPRL1OPRM1OPRK1
SCHEMBL1134375 0.93 OPRM1 (0.41) OPRL1OPRM1OPRK1
SCHEMBL1134350 0.93 OPRM1 (0.41) OPRL1OPRM1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275574-A1 NOVEL COMPOUNDS-300 ASTRAZENECA AB (SE) 2009-11-05 US disclosed
US-20090275574-A1 NOVEL COMPOUNDS-300 ASTRAZENECA AB (SE) 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275574-A1 NOVEL COMPOUNDS-300 CACNA1A, SCN10A, OPRM1 OPRL1 4/4885OPRM1 3/4885OPRK1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.